<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210811052145N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-09-29</date_registration>
      <primary_sponsor>Bandare-abbas University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effectiveness of cefazolin-heparin lock therapy and ethanol-heparin lock therapy on the persistence and site infection in hemodialysis catheter patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of cefazolin-heparin lock therapy and ethanol-heparin lock therapy on the persistence and site infection in hemodialysis catheter patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58037</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this study, a simple and individual random method was used. In this way, based on the sample size of the study and using the table of random number allocation, 80 codes from number one to eighty were assigned to patients (Randomized Allocation). Then the patients were randomly assigned to two intervention groups. ELT (Ethanol lock therapy) expression was considered for ethanol block group and ALT(Antibiotic lock therapy) expression was considered for cefazolin block group. Finally, after the researcher referred to the hemodialysis center, the eligible patients were assigned to two intervention groups based on the order of randomized codes, Blinding description: In this study, nurses and statistical analysts are unaware of the type of block and groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>catheters site infection in hemodialysis pationts.</hc_freetext>
      <i_freetext>Intervention 1: ethanol-heparin block group: In the ethanol-heparin block group, participants received routine and standardized care after the end of the hemodialysis process, which included rinsing the catheter lumens with normal saline. Finally, the ethanol-heparin block solution with a ratio of 2 (ethanol) to 1 (heparin) was blocked by a research colleague according to the volume of catheter lumens. It should be noted that the volume of the catheter lumens is about 3CC. The solution remains in the catheter until the next visit. At the next visit before hemodialysis, first evaluate the patient, including weight control and blood pressure by the researcher and complete the checklist for catheter infection according to the CDC criteria, which includes redness, tenderness, hardening of the catheter tissue about 2 cm, presence Or the absence of fever was done by the researcher and the ward manager. The blocked solution is then aspirated and hemodialysis is started. Intervention 2: cefazolin lock group: In the cephazolin-heparin block group, after the end of the hemodialysis process, they received routine and standard care, which included rinsing the catheter lumens with normal saline, then cefazolin-heparin block solution with a ratio of 2 (cefazolin) to 1 (heparin). Was ready, Due to the lumen volume, the catheter was blocked by a research colleague. It should be noted that the volume of the catheter lumens is about 3CC. The solution remains in the catheter until the next visit. At the next visit before hemodialysis, the patient first evaluates the patient, including weight control and blood pressure, and completes a checklist for catheter infection according to the CDC criteria, which includes redness, tenderness, and hard The tissue of the catheter site is about 2 cm, the presence or absence of fever, was done by the researcher and the ward manager. Then the blocked solution is aspirated and hemodialysis is started. The solution remains in the catheter until the next visit. At the next visit before hemodialysis, first evaluate the patient, including weight control and blood pressure by the researcher and complete the checklist for catheter infection according to the CDC criteria, which includes redness, tenderness, hardening of the catheter tissue about 2 cm, presence Or the absence of fever was done by the researcher and the ward manager. The blocked solution is then aspirated and hemodialysis is started.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Due to the privacy of the participants</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Mehdi Hosseinifard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.14, 28Ave., Fadaeian Blvd., Farrokhshahr Town</address>
        <city>Farrokhshahr</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8831855659</zip>
        <telephone>+98 38 3242 9362</telephone>
        <email>mehdi.hosseinifard@yahoo.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.Hadi Yousefi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Hussain Boulevard</address>
        <city>Bandar Abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7916613885</zip>
        <telephone>+98 76 3334 4429</telephone>
        <email>hadiyousefi17@gmail.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Informed consent
Referral and introduction of the patient by the physician
over 18 years old</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Lack of willingness to participate
use of systemic antibiotics
Use of immunosuppressive drugs
Having a previous catheter or systemic infection</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>ethanol-heparin block group: In the ethanol-heparin block group, participants received routine and standardized care after the end of the hemodialysis process, which included rinsing the catheter lumens with normal saline. Finally, the ethanol-heparin block solution with a ratio of 2 (ethanol) to 1 (heparin) was blocked by a research colleague according to the volume of catheter lumens. It should be noted that the volume of the catheter lumens is about 3CC. The solution remains in the catheter until the next visit. At the next visit before hemodialysis, first evaluate the patient, including weight control and blood pressure by the researcher and complete the checklist for catheter infection according to the CDC criteria, which includes redness, tenderness, hardening of the catheter tissue about 2 cm, presence Or the absence of fever was done by the researcher and the ward manager. The blocked solution is then aspirated and hemodialysis is started.</i_keyword>
      <i_keyword>cefazolin lock group: In the cephazolin-heparin block group, after the end of the hemodialysis process, they received routine and standard care, which included rinsing the catheter lumens with normal saline, then cefazolin-heparin block solution with a ratio of 2 (cefazolin) to 1 (heparin). Was ready, Due to the lumen volume, the catheter was blocked by a research colleague. It should be noted that the volume of the catheter lumens is about 3CC. The solution remains in the catheter until the next visit. At the next visit before hemodialysis, the patient first evaluates the patient, including weight control and blood pressure, and completes a checklist for catheter infection according to the CDC criteria, which includes redness, tenderness, and hard The tissue of the catheter site is about 2 cm, the presence or absence of fever, was done by the researcher and the ward manager. Then the blocked solution is aspirated and hemodialysis is started. The solution remains in the catheter until the next visit. At the next visit before hemodialysis, first evaluate the patient, including weight control and blood pressure by the researcher and complete the checklist for catheter infection according to the CDC criteria, which includes redness, tenderness, hardening of the catheter tissue about 2 cm, presence Or the absence of fever was done by the researcher and the ward manager. The blocked solution is then aspirated and hemodialysis is started.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Prevention of catheter site infection. Timepoint: daily. Method of measurement: Redness - Sensitivity to touch - Hardening of catheter tissue about 2 cm - No fever or fever.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Increased catheter durability. Timepoint: daily. Method of measurement: From the time the catheter is inserted until the onset of symptoms of infection.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>researcher</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-05-29</approval_date>
        <contact_name>Ethics comittee of hormozgan University of Medical Sciences</contact_name>
        <contact_address>Islamic Republic of Iran Blvd, shahid mohammadi hospital Bandar abbas Hormozgan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
